HCA Midwest Health, Kansas City’s leading healthcare and cancer care provider, announces the opening of the Blood Cancer Center of Sarah Cannon HCA Midwest Health located at Research Medical Center. The program provides comprehensive outpatient services and a dedicated inpatient oncology unit designed to care for patients with complex malignant blood disorders. Led by Medical Director Frank Slovick, M.D., a board certified medical oncologist and hematologist, the Blood Cancer Center of Sarah Cannon HCA Midwest care team comprises other blood cancer specialists including Jaswinder Singh, M.D., board certified medical oncologist and hematologist; Julie Wilhauk, DNP, APRN, AOCNP, nurse practitioner, Jenna Bell, RN, BSN, OCN, blood cancer nurse navigator; and a staff of cancer certified nurses, providing compassionate, high-quality cancer care.
“The Blood Cancer Center of Sarah Cannon HCA Midwest Health is committed to providing an unparalleled experience for patients seeking treatment for blood cancer,” Dr. Slovick says. “These patients have very unique needs, requiring care from a highly specialized team. Our inclusion in the Sarah Cannon Blood Cancer Network assures access to new therapies for our patients while combining a comprehensive team of specialists.”
The Blood Cancer Center of Sarah Cannon HCA Midwest Health builds upon our strong reputation in cancer by delivering expanded treatment and research options for our patients,” says M.L. Lagarde III, President, HCA Midwest Health. “Our combined efforts and passion will ensure that blood cancer patients across the region have better access to the most innovative, cutting-edge and personalized care throughout the cancer treatment journey and is another example of how Sarah Cannon HCA Midwest Health has invested in our community.”
Sarah Cannon, an internationally recognized and highly respected name in cancer, and HCA Midwest Health launched an integrated cancer initiative in 2014 to fulfill the mission of advancing science and transforming cancer care in the region. Through this collaboration, Sarah Cannon HCA Midwest Health’s clinical programs are expanding treatments options, developing physician-led centers of excellence, and providing patients access to world-class clinical trials. Sarah Cannon has one of the world’s largest early-phase drug development programs and has conducted more than 150 “first-in-man” clinical trials over its more than 20 years of advancing therapies for patients through clinical research. Most recently, Sarah Cannon has held a leadership role in the development of more than 75 percent of cancer drugs approved in the last three years.
The Blood Cancer Center of Sarah Cannon HCA Midwest Health offers an Oncology Alert Patient Care Program, the only program in the region that focuses on promptly identifying and treating immunocompromised cancer patients arriving through the Emergency Room.
For more information, visit hcamidwest.com/cancer or call (816) 276-4700.